Glucagon-like peptide-1 (GLP-1), corticotropin-releasing hormone (CRH), and hypothalamic neuronal histamine suppress food intake, a target of leptin action in the brain. This study examined the interactions of GLP-1, CRH, and histamine downstream from the leptin-signaling pathway in regulating feeding behavior. Infusion of GLP-1 into the third cerebral ventricle (i3vt) at a dose of 1 µg significantly decreased the initial 1 h cumulative food intake in rats as compared with phosphate-buffered saline (PBS) controls. The GLP-1-induced suppression of feeding was partially attenuated by intraperitoneal pretreatment with α-fluoromethylhistidine (FMH), a specific suicide inhibitor of histidine decarboxylase, which depletes hypothalamic neuronal histamine. Pretreatment with α-helical CRH (10 µg/rat, i3vt), a nonselective CRH antagonist, abolished the GLP-1-induced suppression of feeding completely. I3vt infusion of GLP-1 increased the CRH content and histamine turnover assessed using the pargyline-induced accumulation of tele-methyl histamine (t-MH), a major metabolite of neuronal histamine, in the hypothalamus. The central infusion of CRH also induced the increase of histamine turnover and CRH receptor type 1 was localized on the cell body of histamine neuron. Pretreatment with exendin(9-39), a GLP-1 receptor antagonist, attenuated the leptin-induced increase in CRH content of the hypothalamus. Finally, i3vt infusion of leptin also increased histamine turnover in the hypothalamus. Pretreatment with exendin(9-39), α-helical CRH or both antagonists attenuated the leptin-induced responses of t-MH levels in the hypothalamus. These results suggest that CRH or hypothalamic neuronal histamine mediates the GLP-1-induced suppression of feeding behavior, that CRH mediates GLP-1 signaling to neuronal histamine and that a functional link from GLP-1 to neuronal histamine via CRH constitutes the leptin-signaling pathway regulating feeding behavior.
food intake acutely, and chronic central administration reduces body weight (1, (3) (4) (5) (6) . Importantly, i3vt injection of exendin(9-39), a specific GLP-1 receptor antagonist, increases food intake in several animal models (7, 8) , indicating that endogenous GLP-1 inhibits feeding behavior. Furthermore, a recent study revealed that i3vt injection of GLP-1 activated the hypothalamo-pituitary-adrenocortical axis primarily by stimulating corticotropin-releasing hormone (CRH) neurons, suggesting that CRH mediates the anorectic action of GLP-1 (9) .
Leptin, which is secreted by adipose tissue, reduces food intake and body weight by affecting a variety of hypothalamic orexigenic and anorexigenic substances (10) . Administration of leptin increases the expression of CRH mRNA, an inhibitor of food intake, via leptin receptors expressed in the PVN (11, 12) . GLP-1 is another target by which leptin suppresses food intake (13) . Leptin receptors have been localized to GLP-1 neurons (13) . In addition, the administration of exendin(9-39), a specific GLP-1 receptor antagonist, acutely attenuates the leptin-induced reduction in food intake and body weight (13) .
Histamine is another brain substance that suppresses appetite. Hypothalamic neuronal histamine originating in the tuberomammillary nucleus (TMN) of the posterior hypothalamus has diffuse projections throughout the brain, including the PVN and ventromedial hypothalamic nucleus (VMH) as a satiety center. There is evidence that neuronal histamine inhibits feeding behavior via H 1 -receptors (H 1 -R) in the VMH and PVN (14) . Recent studies have shown that hypothalamic neuronal histamine is one of the targets of leptin action in the brain. Central administration of leptin increases histamine turnover in the hypothalamus (15) . Leptin-induced suppression of feeding is attenuated in rats in which histamine has been depleted with α-fluoromethylhistidine (FMH), a suicide inhibitor of histidine decarboxylase (HDC), and in histamine H 1 -R knockout mice (15) . However, it is still not clear how leptin regulates hypothalamic neuronal histamine. Because no leptin receptors have been identified in histamine neurons in the TMN, another leptin responsive-pathway may mediate leptin signaling to histamine neurons. CRH is one candidate for such action, because central administration of CRH increases histamine turnover (16) .
Therefore, GLP-1, CRH, and hypothalamic neuronal histamine act as anorexigenic substances under the control of leptin. We hypothesized that these substances constitute a neuronal network that transduces leptin signaling in the hypothalamus. To examine this hypothesis, we investigated whether pretreatment with α-helical CRH 9-41 (α-hCRH), a CRH antagonist, or FMH influences the anorectic action of GLP-1; whether a central infusion of GLP-1 affects the CRH content and histamine turnover; whether a central infusion of CRH affects histamine turnover, and whether exendin(9-39) affects the leptin-induced changes in CRH content and histamine turnover in the hypothalamus.
MATERIAL AND METHODS

Animals
Male Sprague-Dawley (SD) rats, weighing 250-280 g, were housed in a room illuminated daily from 0700 to 1900 (12-h light-dark cycle) and maintained at 21 ± 1°C and a humidity of 55 ± 5%. They were allowed free access to standard rat chow (Clea rat chow, Clea, Japan) and tap water. All of the rats were handled for 5 min on four successive days to equilibrate their arousal levels before the experiment (17) . On the testing day, they were ascertained to have recovered to at least the pretreatment body weight. All studies were conducted in accordance with the Oita Medical University Guidelines based on the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Surgery
Under intraperitoneal sodium pentobarbital anesthesia (50 mg/kg), the SD rats were placed in a stereotaxic apparatus (Narishige, Tokyo), and a stainless steel guide cannula (23 gauge) was implanted in the third cerebroventricle at least 10 days before starting the infusion. A stainless steel wire stylet (30 gauge) was inserted in the guide cannula to prevent leakage of the cerebrospinal fluid and obstruction of the cannula. A 23-gauge 15-mm-long stainless steel cannula was inserted into the third ventricle at the midline 6.0 mm anterior to ear bar zero to a depth of 7.8 mm from the cortical surface, according to the atlas of Paxinos and Watson (18) . Details of the surgical procedure have been described previously (19) .
Reagents
GLP-1, leptin, α-hCRH, exendin(9-39), pargyline hydrochloride (Sigma, St. Louis, MO), and FMH (Research Biochemical International, Natick, MA) were freshly dissolved in phosphate-buffered saline (PBS) on the day of administration. The pH of each solution was adjusted to 6.5-7.5.
Measuring food intake
Measuring food intake after administering GLP-1 pretreated with FMH
Food intake was measured for 1 h after the i3vt administration of PBS, GLP-1, FMH, or GLP-1 pretreated with FMH. Twenty-four rats were divided into 4 groups of 6 rats each, matched by body weight. The food was removed 24 h before the experiment. On the experiment day, FMH (50 mg/kg/0.5 ml intraperitoneally: a dose previously determined to deplete most neuronal histamine in the hypothalamus) was administered centrally 2 h before GLP-1 (1 µg/10 µl for 10 min) or PBS infusion (1 µl/min for 10 min) per rat through the third ventricle cannula. The same volume of PBS or FMH was administered intraperitoneally 2 h before the central infusion of GLP-1 or PBS to the other groups.
Measuring food intake after administering GLP-1 pretreated with α-hCRH
Food intake was measured for 1 h after i3vt administration of PBS, GLP-1, α-hCRH, or GLP-1 pretreated with α-hCRH. Twenty-four rats were divided into 4groups of 6 rats each matched by body weight. The food was removed 24 h before the experiment. On the experiment day, α-hCRH (1 µg/µl/min for 10 min) was administered centrally 2 h before GLP-1 (1 µg/10 µl for 10 min) or PBS infusion (1 µl/min for 10 min) per rat through the third ventricle cannula. A volume of PBS equal to that of α-hCRH was administered centrally 2 h before the central infusion of GLP-1 or PBS to the other groups.
Measuring CRH, histamine, and t-MH contents in discrete hypothalamic nuclei
SD rats were pretreated with pargyline hydrochloride (0.33 mmol/kg), an inhibitor of monoamine oxidase B, which induces accumulation of t-MH in the extraneuronal space as a major metabolite of released neuronal histamine or PBS intraperitoneally 2 h before the central infusion of either GLP-1 (1 µg/10 µl for 10 min) or PBS (1 µl/min for10 min). Sixty rats were divided into 10 groups of 6 rats each, matched by body weight. The groups received GLP-1 (1 µg/10 µl) pretreated with PBS (10 µl), (two groups, one for CRH and another for histamine and t-MH), CRH (0.1 nmol/10 µl) pretreated with PBS (10 µl), CRH (0.1 nmol/10 µl) pretreated with α-hCRH (10 µg/10 µl), leptin (1 µg/10 µl) pretreated with PBS (10 µl), leptin (1 µg/10 µl) pretreated with exendin(9-39) (100 µg/10 µl) (two groups, one for CRH and another for histamine and t-MH), leptin (1 µg/10 µl) pretreated with α-hCRH (10 µg/10 µl), leptin (1µg/10 µl) pretreated with exendin(9-39) (100 µg/10 µl) plus α-hCRH (10 µg/10 µl) or PBS (20 µl) infused for 20 min into third ventricle at a rate of 1 µl/min. All the rats were anesthetized with sodium pentobarbital (50 mg/kg, intraperitoneally) and exsanguinated following transcardiac perfusion with 100 ml of saline containing 200 units of heparin. After decapitation, the brain was removed, and the diencephalic tissue was frozen quickly in liquid nitrogen. Sections containing the lateral hypothalamus (LH), PVN, VMH, and TMN were dissected with a frozen razorblade, at the appropriate levels, based on the rat brain map by Paxinos and Watson (18) . These nuclei were collected and placed in 400 µl of 0.5-M acetic acid and homogenated. The homogenate of each sample was boiled for 10 min and a 50-µl sample was removed for protein assay (Bio-Rad, Hercules, CA). The CRH content was measured in a 100-µl sample using a CRH RIA kit (Peninsula Laboratories, Belmont, CA). The histamine content was measured in a 50-µl sample using a histamine RIA kit (Eikenkagaku Co., Tokyo, Japan), and the tele-methylhistamine (t-MH) content was measured in a 40-µl sample using a t-MH RIA kit (Pharmacia-Upjohn, Tokyo, Japan).
Immunohistochemistry
The rats were anesthetized by ip injection of 50 mg/kg sodium pentobarbital, and killed by transcardiac perfusion with 50 ml PBS that contained 50 units of heparin, followed by 500 ml 4% 1-ethyl-3 carbodiimide, followed by 50 ml 4% paraformaldehyde in ice-cold PBS. The brain was removed and divided into three segments, that is, the forebrain, the diencephalons, and the brainstem. The diencephalic tissue was placed in PBS overnight. The specimens were transferred to a 20% sucrose solution for two days, then to a 30% sucrose solution for three days. The specimens were then frozen rapidly at -80°C and sectioned at a thickness of 40 µm using a cryostat at -20°C. The sections were treated with 0.1% H 2 O 2 in PBS for 30 min, presoaked for 1 h in PBS that contained 0.3% Triton X-100 (Sigma), 2% bovine serum albumin, and 2% normal goat serum (NGS) or 2% normal rabbit serum (NRS). The sections were incubated overnight at room temperature with the primary antiserum in a buffer that contained 0.3% Triton X-100, 1% NGS, and 0.1% sodium azide (Sigma). Biotinylated horseradish peroxidase (HRP) complex (ABC reagent; Vector Laboratories, Burlingame, CA) was then added. The tissues were rinsed 3 times in PBS, with agitation after each step. The HRP label was visualized by reaction for 3 min in 0.05% 3,3′-diaminobenzidine (DAB)-HCl in 0.1 M Tris buffer (pH 7.5) that contained 0.3% H 2 O 2 . Some of the sections were double-labeled with antigens, histamine antiserum (1:500; Chemicon Inc., Temecula, CA), CRH type 1 receptor (CRH1-R) and CRH type 2 receptor (CRH2-R) antiserum (1:500; Santa Cruz Biotechnology, Santa Cruz, CA), followed by detection with HRP-and fluorescein-5-isothiocyanate (FITC)-labeled secondary antibodies.
Statistics
The data were expressed as the means ± SEM. Statistical evaluation consisted of an ANOVA followed by a post hoc Fisher's PLSD test. For all tests, the level of significance was set at P < 0.05.
RESULTS
Effect of pretreatment with FMH or α-hCRH on the GLP-1-induced suppression of food intake
I3vt infusion of GLP-1 at a dose of 1 µg significantly decreased the initial 1 h cumulative food intake as compared with PBS controls (GLP-1: 1.34±0.43 g, PBS: 4.14±0.29 g, n=6 each, P<0.01) (Fig. 1) . Intraperitoneal pretreatment with FMH partially attenuated the GLP-1-induced suppression of food intake (GLP-1+PBS: 1.34±0.43 g, GLP-1+FMH: 2.34±0.16 g, n=6 each, P<0.05) (Fig. 1) . Administration of FMH alone did not affect the cumulative food intake as compared with the PBS group (Fig. 1) . The GLP-1-induced suppression of food intake was abolished by pretreatment with α-hCRH (GLP-1+PBS: 2.21±0.35 g, GLP-1+α-hCRH: 3.98±0.38 g, n=6 each, P<0.05) (Fig. 2) . Treatment with α-hCRH alone did not alter feeding as compared with the PBS group (Fig. 2) .
Effect of a central infusion of GLP-1 on the CRH, histamine, and t-MH contents in different hypothalamic nuclei
I3vt infusion of GLP-1 at a dose of 1 µg/rat increased the CRH content in the PVN and TMN as compared with PBS controls, but not in other nuclei (n=6 each, P<0.05) (Fig. 3) . The central administration of GLP-1 increased the histamine content in the TMN (n=6 in each, P<0.05) (Fig.  4A ) and increased the pargyline-induced accumulation of t-MH in the TMN, PVN, and VMH as compared with the PBS group (n=6 each, P<0.05) (Fig. 4B) .
Change in the histamine and t-MH contents with the central infusion of CRH and α-hCRH
A bolus i3vt infusion of CRH did not affect the concentrations of histamine in the hypothalamic nuclei, with the exception of the TMN, in which the infusion elevated the histamine concentration, as compared with PBS infusion (P<0.05) (Fig. 5A) . However, the accumulation of t-MH was more accelerated after CRH infusion than after PBS infusion (P<0.05), not only in the TMN, but also in the PVN and the VMH (Fig. 5B) . Pretreatment with α-hCRH suppressed the increase of histamine and t-MH by CRH infusion in the hypothalamus (Fig. 5) .
Immunohistochemical staining of histamine cell bodies for CRH1-R and CRH2-R
The histamine cell body, CRH1-R, and CRH2-R in the TMN were double-labeled immunohistochemically, as shown in Fig. 6 . CRH1-R was localized the histamine cell body (Fig.  6A) . In contrast to the positive staining for CRH1-R, CRH2-R was not present on the histamine cell bodies (Fig. 6B) .
Change in the t-MH and CRH contents with a central infusion of leptin and exendin(9-39) or α-hCRH
Central infusion of leptin at a dose of 1 µg/rat increased the CRH content in the TMN, PVN, and VMH (n=6 each, P<0.05) as compared with the PBS group. Pretreatment with exendin(9-39) attenuated these effects of leptin (n=6 each, P<0.05) (Fig. 7) . Furthermore, central infusion of leptin increased the pargyline-induced accumulation of t-MH in the TMN, PVN, and VMH as compared with the PBS group (n=6 each, P<0.05). Pretreatment with exendin(9-39), α-hCRH or exendin(9-39) plus α-hCRH attenuated the effects of leptin on t-MH (n=6, P<0.05) (Fig. 8) . In the LHA, there were no significant differences in the CRH and t-MH contents among the PBS, leptin, and leptin pretreated with each antagonist groups. DISCUSSION GLP-1, CRH, and hypothalamic neuronal histamine act as anorexigenic substances in the hypothalamus under the control of leptin (9, 13, 15) . However, their functional relationships, especially between GLP-1 and histamine, are still uncertain. Present study demonstrated that the depletion of neuronal histamine by pretreatment with FMH partially attenuated the GLP-1-induced suppression of food intake. This indicates that endogenous neuronal histamine mediates the suppressive effect of GLP-1 on food intake. Therefore, it is important to analyze how GLP-1 affects hypothalamic neuronal histamine. The transmethylation of histamine into t-MH, a major metabolite of histamine, and its subsequent deamination, is the major metabolic pathway of histamine in the brain. Histamine released from a nerve terminal is rapidly converted into its metabolite, t-MH. Therefore, it is much more informative to analyze histamine release by measuring its metabolite than to rely on a measurement of the brain histamine level itself. Pretreatment with pargyline, an inhibitor of monoamine oxidase B, is useful for this assessment, as it induces the accumulation of t-MH in the extraneuronal space (20, 21) . We showed that a central infusion of GLP-1 increased the levels of both amines in the TMN, the origin of histamine neurons, but only the t-MH level in the PVN and VMH, the sites that histamine neurons project to. Therefore, we speculate that central infusion of GLP-1 increases histamine turnover, synthesis, and release, in the PVN and VMH. Therefore, we speculate that GLP-1 suppresses feeding in part via the activation of neuronal histamine.
Nevertheless, a neuroanatomical study failed to confirm a functional linkage between GLP-1 and neuronal histamine. No neuronal projections of GLP-1-containing neurons or localization of GLP-1 receptors was identified in the TMN, the site of histamine neuron cell bodies. One possible explanation is that GLP-1 influences histamine release from the nerve terminal at the projection site of histamine neurons. In fact, GLP-1 increased histamine turnover in the PVN and VMH. However, this is unlikely, because administration of GLP-1 affected both the histamine and t-MH contents in the TMN. Rather, it is reasonable to postulate that GLP-1 affects neuronal histamine via the mediation of other GLP-1 responsive substance(s). So far, CRH is the best candidate, since CRH neurons in the PVN are a major target of GLP-1 action in the hypothalamus (9, 22) . Previous studies showed that central administration of GLP-1 increased corticosterone in rats and activated c-fos expression in CRH neurons in the PVN (9) . In humans, the intravenous infusion of GLP-1 increased both ACTH and plasma cortisol (23) . Furthermore, GLP-1 neurons stimulate CRH neurons via the GLP-1 receptor (GLP-1-R) (24) . These results are consistent with our findings, in which the central infusion of GLP-1 elevated the CRH content in the PVN. In addition, we demonstrated that pretreatment with α-hCRH, a CRH antagonist, completely attenuated GLP-1-induced suppression of food intake. Finally, it is necessary to discuss the relationship between CRH and neuronal histamine. First, our previous study demonstrated that central administration of CRH increased histamine turnover in the hypothalamus (16) . Second, the CRH-induced increase in histamine turnover was suppressed by pretreatment with α-hCRH in the present study. Third, we identified the neurohistological expression of CRH type 1 receptors on histamine neuron cell bodies in the TMN. Therefore, we hypothesized that CRH mediates GLP-1 signaling to neuronal histamine. This hypothesis was supported by our finding that the GLP-1-induced increase in histamine turnover in each nucleus was attenuated by pretreatment with α-hCRH.
GLP-1 is a potential target for leptin in the control of feeding behavior, because the long isoform leptin receptor is localized to GLP-1 neurons (13) . In addition, acute administration of exendin(9-39) greatly attenuates leptin-induced reductions in food intake and body weight (13) . Like GLP-1, both CRH and neuronal histamine are under the control of leptin (11) . Next, we analyzed how the neuronal linkage from GLP-1 to neuronal histamine via CRH functions downstream in the leptin pathway. First, we found that pretreatment with exendin(9-39) attenuated the leptin-induced increase in the CRH content of the PVN, indicating that GLP-1 mediates leptin signaling to CRH neurons in the PVN. Second, the leptin-induced increase in the t-MH content was also attenuated by pretreatment with exendin(9-39) in the TMN, PVN, and VMH. This indicates that GLP-1 mediates leptin signaling to neuronal histamine. Finally, the leptin-induced increase in histamine turnover was attenuated by pretreatment with α-hCRH, indicating CRH as a mediator for leptin signaling to neuronal histamine. We therefore conclude that there is a signaling cascade from leptin to GLP-1, CRH, and neuronal histamine.
The anorectic effects of GLP-1 may be mediated through neuropeptide Y (NPY) signaling because GLP-1 inhibited and exendin(9-39) augmented NPY-induced feeding, respectively (1, 25) . Recently, leptin has been shown to induce rewiring of the hypothalamic neuronal circuitry, including NPY and pro-opiomelanocortin (POMC) system (26) . Our previous studies showed no functional relationship between histamine system and NPY or POMC system (16, 27) . Therefore, it is not likely that GLP-1-CRH-histamine system may contribute to this leptin-induced rewiring of neuron network. This study provides novel insight into the action of leptin in the hypothalamus for regulating energy metabolism. 8 . The t-MH content of each hypothalamic nucleus after central infusion of leptin, leptin pretreated with exendin(9-39), leptin pretreated with α-hCRH, leptin pretreated with exendin(9-39) plus α-hCRH or PBS: i3vt administration of PBS (n=6), leptin: i3vt administration of leptin (1 µg) (n=6), α-hCRH+leptin; i3vt administration of leptin (1 µg) pretreated with α-hCRH (10 µg) (n=6), exendin(9-39)+leptin; i3vt administration of leptin (1 µg) pretreated with exendin(9-39) (100 µg) (n=6), α-hCRH+exendin(9-39)+leptin; i3vt administration of leptin (1 µg) pretreated with α-CRH (10 µg) plus exendin(9-39) (100 µg) (n=6). *P < 0.05 vs. PBS, #P < 0.05 vs. leptin. 
